BioCatch vs Abnormal Security
In-depth comparison — valuation, funding, investors, founders & more
🇮🇱 Israel · Avi Turgeman
Valuation
$1B
Total Funding
$213M
100-500 employees
🇺🇸 United States · Evan Reiser
Valuation
$5.1B
Total Funding
$546M
650 employees
Analyst Summary
Generated from real data · No AI hallucinations
Both BioCatch and Abnormal Security compete directly in the AI Security space, making this a head-to-head matchup within the same market segment. BioCatch provides behavioural biometrics and fraud prevention AI that analyses how users physically interact with digital devices — mouse movements, typing cadence, touch pressure, and navigation patterns — to authenticate genuine users and detect account takeover, social engineering, and application fraud in real time during banking and financial transactions. Abnormal Security is an AI-focused cybersecurity company founded in 2018 that specializes in email and cloud security.
Abnormal Security carries a valuation of $5.1B, which is 5.1x higher than BioCatch's $1B. On the funding side, Abnormal Security has raised $546M in total — $333M more than BioCatch's $213M.
BioCatch has 7 years more market experience, having been founded in 2011 compared to Abnormal Security's 2018 founding. Both companies are currently at the Series D stage of their journey.
BioCatch operates out of 🇮🇱 Israel while Abnormal Security is based in 🇺🇸 United States, giving each a distinct home-market advantage. On Awaira's 0–100 composite score, both companies are closely matched — BioCatch scores 80 and Abnormal Security scores 80.
Metrics Comparison
| Metric | BioCatch | Abnormal Security |
|---|---|---|
💰Valuation | $1B | $5.1BWINS |
📈Total Funding | $213M | $546MWINS |
📅Founded | 2011 | 2018WINS |
🚀Stage | Series D | Series D |
👥Employees | 100-500 | 650 |
🌍Country | Israel | United States |
🏷️Category | AI Security | AI Security |
⭐Awaira Score | 80 | 80 |
Key Differences
Valuation gap: Abnormal Security is valued 5.1x higher ($5.1B vs $1B)
Funding gap: Abnormal Security has raised $333M more ($546M vs $213M)
Market experience: BioCatch has 7 years more (founded 2011 vs 2018)
Team size: BioCatch has 100-500 employees vs Abnormal Security's 650
Market base: 🇮🇱 BioCatch (Israel) vs 🇺🇸 Abnormal Security (United States)
Direct competitors: Both operate in the AI Security market segment
Which Should You Choose?
Use these signals to make the right call
Choose BioCatch if…
Top Pick- ✓More market experience — founded in 2011
- ✓Israel-based for regional compliance or proximity
- ✓BioCatch provides behavioural biometrics and fraud prevention AI that analyses how users physically interact with digital devices — mouse movements, typing cadence, touch pressure, and navigation patterns — to authenticate genuine users and detect account takeover, social engineering, and application fraud in real time during banking and financial transactions
Choose Abnormal Security if…
- ✓More established by valuation ($5.1B)
- ✓Stronger investor backing — raised $546M
- ✓United States-based for regional compliance or proximity
- ✓Abnormal Security is an AI-focused cybersecurity company founded in 2018 that specializes in email and cloud security
Funding History
BioCatch raised $213M across 0 rounds. Abnormal Security raised $546M across 8 rounds.
BioCatch
No public funding data available.
Abnormal Security
Series D
May 2023
Lead: ICONIQ Growth
Series C
Mar 2022
Lead: Sequoia Capital
Series D
Jan 2022
Series B
Feb 2021
Lead: Sequoia Capital
Series C
Jan 2021
Series A
Mar 2020
Lead: Sequoia Capital
Series B
Jan 2020
Series A
Jan 2019
Lead: Accel Partners
Investor Comparison
No shared investors detected between these two companies.
Unique to Abnormal Security